ANTI-TUMOUR TREATMENTResveratrol in the chemoprevention and treatment of hepatocellular carcinoma
Introduction
Primary liver cancer, also known as hepatocellular carcinoma (HCC), happens to be the sixth most common cancer as well as the third leading cause of cancer mortality in the world.1 HCC has a poor prognosis with the number of deaths almost equal to the number of cases being diagnosed annually (about 600,000) and the 5-year survival rate reported below 9%.2 The incidence of HCC is on the rise in multiple geographic areas, including Asia Pacific, sub-Saharan Africa, southern Europe as well as North America. The occurrence of HCC in the United States has dramatically increased by more than 70% over the last 25 years.3 It has been estimated that there will be more than 22,000 new cases and about 18,000 deaths in the United States in 2009 due to liver cancer which represents about 4% of cancer mortality in this country.4 The vast majority of HCC cases are attributable to underlying infections caused by the hepatitis B and C viruses5; nevertheless several other risk factors, namely alcoholism, obesity, iron overload, as well as dietary carcinogens, such as aflatoxins and nitrosamines are also involved in its etiology.6, 7, 8, 9
Although surgical resection is currently considered to be the most optimal treatment approach, only 10–20% of HCC patients are candidates for surgery because of tumor size, multifocality, vascular invasion, or hepatic decompensation. In addition, for those undergoing resection, the recurrence rates can be as high as 50% within several years of surgery.10 While liver transplantation has been successful for the treatment of early-stage liver cancer, regrettably only a small number of HCC patients qualify for transplantation. The potential of this option is limited due to donor organ shortage as well as the rapid and frequent recurrence of HCC in the transplanted liver. At present, there is no proven effective systemic chemotherapy for HCC. Sorafenib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has been shown to prolong the median survival time by nearly three months in patients with advanced HCC.11 Although sorafenib has been approved by the United States Food and Drug Administration for the treatment of unresectable HCC, recent studies indicate severe adverse effects including a significant risk of bleeding.12 Alternative treatment modalities including transcatheter arterial chemoembolization, targeted intra-arterial delivery of Yttrium-90 microspheres, percutaneous intratumor ethanol injection, and radiofrequency ablation are primarily for palliation and are applicable only to patients with localized liver tumors. In view of the limited treatment and grave prognosis of liver cancer, preventive control approaches, notably chemoprevention, have been considered as one of the best strategies in lowering the current morbidity and mortality associated with HCC.13, 14 A detailed understanding of the pathogenesis of HCC holds the promise of finding an effective and novel strategy for the chemoprevention and treatment of liver cancer.
Although the cellular mechanisms contributing to hepatocarcinogenesis are relatively unknown, a connection between inflammation and liver cancer is beginning to be unraveled. During recent years, compelling evidence has accumulated which provides an insight in the role of inflammation in initiation, promotion and progression of HCC.15 Hepatic inflammation, due to exposure to infectious agents (hepatotropic viruses) as well as toxic compounds, may represent an early step in the development of malignancy with genetic and epigenetic events occurring as a later manifestation of a prolonged inflammatory process. Despite intrinsic differences among etiological factors for HCC, a common denominator of the genesis of malignancy happens to be the perpetuation of a wound-healing response triggered by parenchymal cell death, and the ensuing inflammatory reaction.16, 17 It has been shown that HCC almost always develops on a background of chronic liver injury including chronic hepatitis and cirrhosis, which are both considered to be preneoplastic stages of hepatocellular tumor development.18 An expanding body of evidence suggests that inflammation-mediated processes, including the production of cytokines, chemokines, reactive oxygen and nitrogen species, and mediators of the inflammatory pathways may contribute to hepatic neoplasia.19, 20, 21, 22 Environmental insults, including chemical toxicants, act as tumor initiators and/or promoters by inducing steady-state increase in the generation of reactive oxygen species (ROS).23 Oxidative stress, through generation of ROS including singlet oxygen, superoxide anion, hydrogen peroxide and hydroxyl radical, acts as a predisposing factor to hepatocarcinogenesis and is the common driving force of HCC in chronic liver diseases.19, 24 All these findings have led researchers to theorize that the underlying mechanisms which are most pronounced in occurrence and progression of HCC deal with oxidative stress and the accompanying inflammatory insults.
Phytochemicals are widely accepted as validated treatment options for various conditions. Scientific probing into potential benefits of many of these compounds sufficiently defines them as beneficial pharmacological agents. Natural dietary components, obtained from several fruits, vegetables, nuts and spices have drawn a considerable amount of attention due to their demonstrated ability to suppress carcinogenesis in animal models with some of these substances able to partially prevent or delay cancer formation in several high-risk populations.25 Recent evidence has shown that dietary polyphenolic compounds including anthocyanidins from berries, catechins from green tea, curcumin from turmeric, genistein from soy, lycopene from tomatoes, and quercetin from red onions and apples are phytochemicals with significant anticancer properties.26, 27, 28, 29 A variety of bioactive food components have been shown to modify molecular targets involved in inflammation and redox signaling,30, 31 which are implicated in the development and progression of HCC. Supported by several in vitro assays and studies involving animal models as well as humans, evidence is emerging to support potential chemopreventive and chemotherapeutic effects of several phytochemicals in HCC.32 In this context, resveratrol, a naturally occurring antioxidant and antiinflammatory agent, has emerged as the lead promising molecule.
Resveratrol (3,4′,5-trihydroxy-trans-stilbene, Fig. 1) is a phytochemical found in several dietary sources, such as grapes, berries, peanuts as well as red wine. In nature, it functions as a fungicide produced by the plant itself to ward off potentially lethal organisms and counteract environmental stress.33 Its value as a compound beneficial to human health is well documented.34, 35, 36 Perhaps, it is best known as the compound widely considered to be the agent responsible for the “French Paradox”, a phenomenon in which consumption of red wine is thought to reduce the incidence of heart disease.37 Recent studies have indicated that besides red wine, rose and white wine could be cardioprotective as they also contain resveratrol albeit at lesser concentrations than that of red wine.38 Resveratrol can prevent or slow the progression of a wide variety of inflammation-related illnesses, including cancer, neurodegenerative diseases, cardiovascular ailments, ischemic injury, and viral infections, as well as enhance stress resistance and extend the life span of various organisms.34, 35, 39, 40 An impressive body of experimental findings reveals multiple cellular targets of resveratrol affecting cellular proliferation and growth, apoptosis, inflammation, invasion, angiogenesis and metastasis.41, 42 During the past decade, the amount of research on this phytoalexin has soared, and there exists strong evidence which supports resveratrol as a potent chemopreventive and chemotherapeutic agent.
Jang et al.43 first demonstrated the chemopreventive effects of resveratrol in inhibiting multi-stage carcinogenesis (e.g., initiation, promotion and progression). Subsequently, resveratrol has been shown to suppress proliferation of a wide variety of human tumor cells in vitro,44, 45, 46 which have led to numerous pre-clinical animal studies to evaluate the cancer chemopreventive and chemotherapeutic potential of resveratrol.47, 48 Several clinical trials, including one sponsored by the National Cancer Institute, are currently underway to investigate the use of both resveratrol and resveratrol-rich products, for prevention and treatment of colon cancer.48 A significant amount of resveratrol accumulates and is retained in the liver.49, 50, 51, 52 Resveratrol has been shown to inhibit the hepatic carcinogen-activating enzymes, including cytochrome P450 1A1 (CYP1A1) and CYP3A/2 and induce hepatic phase 2 conjugating enzymes, namely NAD(P)H:quinine oxidoreductase, UDP-glucuronosyl transferase and glutathione S-transferase (GST) in vitro and in vivo.53, 54, 55, 56 The resultant effects of these enzyme modulation by resveratrol could be the reduced exposure of cells to carcinogens due to inhibition of carcinogen activation and/or elevated carcinogen detoxification and elimination. The most fascinating property of resveratrol, with regards to liver cancer, is its strong antiinflammatory57 and antioxidant properties,58 as both oxidative stress and inflammation have been strongly implicated in the occurrence and progression of HCC.16, 17, 19, 24 However, despite its great promise, the effects of resveratrol on liver cancer have not been systematically studied until recently. This review critically examines the current knowledge on the mechanism-based chemopreventive and chemotherapeutic potential of resveratrol in in vitro as well as pre-clinical animal models of HCC.
Section snippets
In vitro studies
There is growing in vitro evidence demonstrating the inhibitory effects of resveratrol on liver cancer. According to a study conducted by Delmas et al.59 the proliferation of rat hepatoma Fao and human hepatoblastoma HepG2 cells were negatively impacted by the addition of resveratrol to the culture medium in both dose- and time-dependent fashion. Fao cells were more sensitive than HepG2 cells. Another interesting finding of this study was that the presence of ethanol potentiated the effects of
Toxicity and pharmacokinetic studies
As described above, an impressive number of studies performed using in vitro as well as pre-clinical in vivo animal models indicate that resveratrol may be an effective anticancer agent in humans for prevention and therapy of liver cancer. In order to successfully translate such promising observations into the clinic, studies on potential toxicity as well as bioavailability, pharmacokinetics of resveratrol are essential. Within the past decade, several research groups have evaluated the
Conclusion and future directions
In recent years, epidemiological data have shown an alarming trend in an increased prevalence of hepatocellular carcinoma. This tendency, compiled with the disease’s high rate of mortality due to imperfect treatment methods, has forced researchers to examine preventive approaches as well as alternate routes to treatment. Using naturally occurring compounds, including those derived from fruits, vegetables and herbs, as potential cancer preventive and therapeutic agents has become a fascinating
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Acknowledgements
The authors thank Werner J. Geldenhuys, Ph.D., for technical assistance with the chemical structures. Our research on resveratrol and liver cancer chemoprevention is supported by a Research Incentive Grant from the Ohio Board of Regents, State of Ohio, United States.
References (121)
Hepatocellular carcinoma: recent trends in the United States
Gastroenterology
(2004)Hepatocellular carcinoma
J Hepatol
(2000)- et al.
Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas
Gastroenterology
(2004) - et al.
Molecular pathways in hepatocellular carcinoma
Cancer Lett
(2006) - et al.
The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe
J Hepatol
(2008) - et al.
Hepatocellular carcinoma
Lancet
(2003) - et al.
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and mata-analysis of clinical trials
Lancet Oncol
(2009) Inflammation, HCC and sex: IL-6 in the centre of the triangle
J Hepatol
(2008)- et al.
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?
Mutat Res
(2008) - et al.
Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms
Arch Biochem Biophys
(2009)
Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives
Cancer Lett
Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration
Life Sci
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
Biochem Biophys Res Commun
Toxicogenomics of resveratrol in rat liver
Life Sci
Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes
Eur J Pharmacol
Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action
Cancer Lett
Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells
Life Sci
Chemopreventive properties of trans-resveratrol against the cytotoxicity of chloroacetanilide herbicides in vitro
Int J Hyg Environ Health
Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells
Toxicology
Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation
Biochim Biophys Acta
Resveratrol inhibits tumor necrosis factor-α-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells
Biomed Pharmacother
Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses
Biochimie
Cholangiocarcinoma
Lancet
Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model
Biochem Biophys Res Commun
Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats
Life Sci
Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3′,4,4′-tetrachlorobiphenyl (PCB-77)
Food Chem Toxicol
Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis
Chem Biol Interact
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
Cell
The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful
J Nutr
Ontogenicity evaluation of resveratrol in p53(±) (p53 knockout) mice
Food Chem Toxicol
Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol
Free Rad Biol Med
Safety studies conducted on high-purity trans-resveratrol in experimental animals
Food Chem Toxicol
Ultrasensitivity assay for the three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection
J Chromatogr B Analyt Technol Biomed Life Sci
Absorption of three wine-related polyphenols in three different matrices by healthy subjects
Clin Biochem
Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography
J Chromatogr B Analyt Technol Biomed Life Sci
Global cancer statistics, 2002
CA Cancer J Clin
Hepatocellular carcinoma: epidemiology, risk factors, and screening
Semin Liver Dis
Cancer statistics, 2009
CA Cancer J Clin
Relevance of nitrosamines to human cancer
Carcinogenesis
Sorafenib in advanced hepatocellular carcinoma
N Eng J Med
Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives
J Gastroenterol Hepatol
Translational strategies for cancer prevention in liver
J Natl Cancer Inst
Cancer-related inflammation
Nature
Inflammation and liver cancer: new molecular links
Ann N Y Acad Sci
Genetics of hepatocellular tumors
Oncogene
Oxidative stress and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis
Biol Chem
Nuclear factor-(B and the hepatic inflammation–fibrosis–cancer axis
Hepatology
The I(B kinase – a bridge between inflammation and cancer
Cell Res
NF-(B in liver diseases: a target for drug therapy
J Appl Toxicol
Redox signaling in cancer biology
Antioxid Redox Signal
Cited by (175)
Colon cancer and colorectal cancer: Prevention and treatment by potential natural products
2022, Chemico-Biological InteractionsNatural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
2022, Seminars in Cancer BiologyExploring the role of senescence inducers and senotherapeutics as targets for anticancer natural products
2022, European Journal of PharmacologyCitation Excerpt :Studies have revealed that resveratrol in cellular models can inhibit gastric cancer by increasing the protein levels of CDK inhibitors, including p16 and p21 (Yang et al., 2013). Resveratrol's effects in cancer prevention have also been demonstrated in many cancer cell lines (Ali and Braun, 2014; Bishayee et al., 2010; Juan et al., 2012). Moreover, Cai et al., have suggested that resveratrol appears to inhibit cancer cell proliferation in a dose-dependent manner that seems to be crucial in preventing cancer (Cai et al., 2015).
Analysis of the medication rules of traditional Chinese medicines (TCMs) in treating liver cancer and potential TCMs exploration
2022, Pharmacological Research - Modern Chinese Medicine